NCT04195633 2026-02-27
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
Phase 2 Recruiting
Clinical Trials
10 trialsNCT05534620 2025-12-02
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
medac GmbH
Phase 1 Recruiting
NCT03961919 2023-11-18
FLAT-Auto
IRCCS San Raffaele
Phase 2 Completed
NCT00796068 2023-02-17
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01894477 2021-06-03
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 2 Unknown
NCT00822393 2020-07-30
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
medac GmbH
Phase 3 Completed
NCT02333058 2020-05-04
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
medac GmbH
Phase 2 Completed
NCT00491634 2015-12-02
Treosulfan-based Conditioning for Transplantation in AML/MDS
Sheba Medical Center
Phase 2 Completed
NCT00253513 2012-06-01
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
OHSU Knight Cancer Institute
Phase 1/2 Completed
NCT01062490 2010-02-04
Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)
medac GmbH
Phase 2 Completed